DAX24.853 ±-0,0%Est506.011 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,3100 -0,1%Nas22.597 -2,0%Bitcoin55.810 +0,1%Euro1,1860 -0,1%Öl67,44 -0,2%Gold4.965 +0,9%

Galderma Aktie

Kaufen

Verkaufen

Galderma Aktien-Sparplan Galderma Aktien-Sparplan

163,00 EUR -2,00 EUR -1,21 %

07:31:05

BMN

150,18 CHF +1,10 CHF +0,74 %

12.02.2026

BRX

Galderma jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Bei einem anderen Broker handeln

Smartphone

Marktkap.38,50 Mrd. EUR

KGV117,50Div. Rendite0,15%

WKNA407X6

ISINCH1335392721

SymbolGDERF

Galderma Aktien News

Sortieren:Datum Meistgelesen

08.12.25RTE.ieL'Oreal to up stake in skin care firm Galderma to 20%

08.12.25Financial TimesL’Oréal bets on beauty injectables by doubling Galderma stake

17.03.25PR NewswireGalderma's Differin is helping destigmatize acne care with first in category Roblox experience

WerbungGalderma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

14.01.25BusinesswireGalderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

13.12.24BusinesswireGalderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

13.12.24BusinesswireCHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

28.11.24BusinesswireGalderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

04.11.24BusinesswireCelebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation

25.10.24BusinesswireGalderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends

24.10.24BusinesswireGalderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance

21.10.24BusinesswireASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

29.08.24BusinesswireGalderma Successfully Issued an Inaugural CHF 500 Million Bond

13.08.24BusinesswireGalderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

05.08.24BusinesswireGalderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

30.07.24BusinesswireGalderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

25.07.24BusinesswireGalderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

25.07.24BusinesswirePHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance

19.06.24BusinesswireGalderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

23.05.24BusinesswireGalderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets

07.05.24BusinesswireGalderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries

24.04.24BusinesswireGalderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth

26.03.24BusinesswireGalderma Announces Full Exercise of Over-Allotment Option

Galderma News

Galderma News: auf dieser Seite finden Sie alle Galderma News und Nachrichten zur Galderma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Galderma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Galderma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.